4.5 Article

Resveratrol-Containing Gel for the Treatment of Acne Vulgaris A Single-Blind, Vehicle-Controlled, Pilot Study

期刊

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
卷 12, 期 2, 页码 133-141

出版社

ADIS INT LTD
DOI: 10.2165/11530630-000000000-00000

关键词

-

向作者/读者索取更多资源

Background: Acne vulgaris is a complex, chronic, and common skin disorder of pilosebaceous units. The major pathogenic factors involved are ductal hyperkeratinization, obstruction of sebaceous follicles resulting from abnormal keratinization of the infundibular epithelium, stimulation of sebaceous gland secretion by androgens, and microbial colonization of pilosebaceous units by Propionibacterium acnes, which promotes perifollicular inflammation. Aim: The aim of the study was to investigate the therapeutic effects of resveratrol, a natural phytoalexin produced by some spermatophytes, such as grapes and other plants, on acneic skin. Methods: Resveratrol was incorporated in a carboxymethylcellulose-based gel. The chemical stability of resveratrol after storage at 4 C for 30 days was investigated by high-performance liquid chromatography (HPLC). The resveratrol-containing hydrogel was administered to 20 patients affected by acne vulgaris enrolled in this single-blind study. The resveratrol-containing formulation was applied daily as a solo treatment on the right side of the face for 60 days, while the hydrogel vehicle was applied to the left side of the face as a control. To objectively evaluate the results, a digital photographic database was used to collect images. The number and type of lesions were recorded for each patient, to compare the Global Acne Grading System (GAGS) score before treatment with that obtained at the end of the study. Moreover, with the innovative technique of follicular biopsy, areas of acneic skin were prepared for histopathology. The average area occupied by microcomedones at baseline was compared with that at the end of treatment. Results: HPLC analysis demonstrated that resveratrol, upon incorporation into the gel, did not convert to its cis-isomer when stored at 4 degrees C for 30 days. All patients were satisfied with the active treatment and none experienced adverse effects. Clinical evaluation showed a 53.75% mean reduction in the GAGS score on the resveratrol-treated sides of the face compared with 6.10% on the vehicle-treated sides of the face. These data were supported by histologic analysis, which showed a 66.7% mean reduction in the average area of microcomedones on the resveratrol-treated sides of the face. The comparison with the vehicle-treated side of the face (9.7% reduction) showed a clinically relevant and statistically significant decrease of lesions in areas treated with resveratrol-containing hydrogel. Conclusion: This pilot study showed positive results for resveratrol gel in acne, and should be considered a valid starting point for further testing of the effectiveness of this molecule in different concentrations and formulations and in a larger group of patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Food Science & Technology

Very low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: an update for dermatologists and nutritionists

Luigi Barrea, Matteo Megna, Sara Cacciapuoti, Evelyn Frias-Toral, Gabriella Fabbrocini, Silvia Savastano, Annamaria Colao, Giovanna Muscogiuri

Summary: Psoriasis is a chronic immune-mediated skin disease influenced by genetic and lifestyle factors. Nutrition and obesity are significant contributors to its pathogenesis and severity. Certain diets with anti-inflammatory properties, such as the very-low-calorie ketogenic diet (VLCKD), may improve clinical severity by reducing weight and systemic inflammation.

CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION (2022)

Article Dermatology

Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

Matteo Megna, Eleonora Cinelli, Lucia Gallo, Elisa Camela, Angelo Ruggiero, Gabriella Fabbrocini

Summary: Efficacy and safety of risankizumab were confirmed in the treatment of psoriasis, with significant improvements observed in both PASI and BSA, even in a challenging population of patients with multiple treatment failures.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2022)

Letter Dermatology

Sonidegib treatment in patients with locally advanced basal cell carcinoma

Alessia Villani, Gabriella Fabbrocini, Massimiliano Scalvenzi

DERMATOLOGIC THERAPY (2022)

Letter Dermatology

Leg paralysis after photodynamic therapy for lymphomatoid papulosis: A case report

Lucia Genco, Teresa Battista, Matteo Noto, Mario De Lucia, Eleonora Cinelli, Massimiliano Scalvenzi, Gabriella Fabbrocini, Matteo Megna

DERMATOLOGIC THERAPY (2022)

Article Dermatology

Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study

Delia Colombo, Luca Bianchi, Gabriella Fabbrocini, Salvatore Corrao, Annamaria Offidani, Luca Stingeni, Antonio Costanzo, Giovanni Pellacani, Ketty Peris, Federico Bardazzi, Giuseppe Argenziano, Silvana Ruffolo, Paolo Dapavo, Carlo Carrera, Maria Concetta Fargnoli, Aurora Parodi, Marco Romanelli, Piergiorgio Malagoli, Marina Talamonti, Matteo Megna, Massimo Raspanti, Matteo Paolinelli, Katharina Hansel, Alessandra Narcisi, Andrea Conti, Clara De Simone, Marco Adriano Chessa, Alina De Rosa, Eugenio Provenzano, Michela Ortoncelli, Chiara Moltrasio, Rosaria Fidanza, Martina Burlando, Annalisa Tonini, Francesca Maria Gaiani, Lucia Simoni, Alessandra Ori, Martina Fiocchi, Emanuela Zagni

Summary: The study aimed to provide real-world evidence of the effectiveness of biologics in Italian patients with moderate-severe psoriasis. Results showed that biologics were effective and well tolerated in psoriasis patients, with a high percentage of patients achieving PASI 75 at 16-52 weeks of treatment and a high sustained response rate after 1 year.

DERMATOLOGIC THERAPY (2022)

Letter Dermatology

Dupilumab for the treatment of atopic dermatitis in transplant patients: Two case reports and literature review

Maddalena Napolitano, Mariateresa Nocerino, Vincenzo Picone, Fabrizio Martora, Gabriella Fabbrocini, Stefano Dastoli, Cataldo Patruno

DERMATOLOGIC THERAPY (2022)

Letter Dermatology

Pityriasis rosea after Moderna mRNA-1273 vaccine: A case series

Fabrizio Martora, Gabriella Fabbrocini, Claudio Marasca

DERMATOLOGIC THERAPY (2022)

Editorial Material Pharmacology & Pharmacy

Alitretinoin for the treatment of severe chronic eczema of the hands

Maddalena Napolitano, Luca Potestio, Mario De Lucia, Mariateresa Nocerino, Gabriella Fabbrocini, Cataldo Patruno

Summary: Alitretinoin can be considered as a valid therapeutic option for patients with Chronic Hand Eczema who do not respond to conventional treatments. Clinical trials and real-life experiences have shown that it effectively improves both objective and subjective clinical symptoms, leading to a significant enhancement in patients' Quality of Life. Prior caution should be exercised in patients with certain chronic diseases or women of childbearing age when prescribing alitretinoin.

EXPERT OPINION ON PHARMACOTHERAPY (2022)

Letter Virology

Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies?

Fabrizio Martora, Vincenzo Picone, Luigi Fornaro, Gabriella Fabbrocini, Claudio Marasca

JOURNAL OF MEDICAL VIROLOGY (2022)

Letter Dermatology

Sonidegib efficacy and tolerability in advanced basal cell carcinoma: A single-center real-life experience

Alessia Villani, Gabriella Fabbrocini, Claudia Costa, Massimiliano Scalvenzi

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Article Dermatology

European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement

Z. Apalla, V Nikolaou, D. Fattore, G. Fabbrocini, A. Freites-Martinez, P. Sollena, M. Lacouture, L. Kraehenbuehl, A. Stratigos, K. Peris, E. Lazaridou, B. Richert, E. Vigarios, J. Riganti, B. Baroudjian, A. Filoni, R. Dodiuk-Gad, C. Lebbe, V Sibaud

Summary: The introduction of ICIs revolutionized oncologic therapy but also brought the risk of irAEs, with dermatologic irAEs being common. The EADV task force provided treatment recommendations for skin toxicities, focusing on balancing symptom relief with ongoing oncologic treatment.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Letter Dermatology

Long-term results of teledermatology for acne patients during COVID-19 pandemic

Alessia Villani, Maria Carmela Annunziata, Matteo Megna, Massimiliano Scalvenzi, Gabriella Fabbrocini

JOURNAL OF COSMETIC DERMATOLOGY (2022)

Article Biochemistry & Molecular Biology

A Familial Novel Putative-Pathogenic Mutation Identified in Plaque-Psoriasis by a Multigene Panel Analysis

Marcella Nunziato, Anna Balato, Anna Ruocco, Valeria D'Argenio, Roberta Di Caprio, Nicola Balato, Fabio Ayala, Francesco Salvatore

Summary: Psoriasis is a chronic skin disorder with an immune basis, characterized by red, flaky patches that often release silvery scales. The study aimed to determine if there are genetic alterations that can explain the onset of the disease by using next-generation sequencing technologies and a multigene panel. Variants associated with psoriasis were found in the TRAF3IP2 gene, and a missense variant was found in the NAT9 gene. The use of multigene panels can help identify new susceptibility genes and allow for early diagnoses in affected families.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Pathology

Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases

Giuseppe Broggi, Maria Failla, Andrea Russo, Antonio Longo, Andrea Palicelli, Magda Zanelli, Claudia Lombardo, Carla Loreto, Francesco Merolla, Rosa Maria Di Crescenzo, Gennaro Ilardi, Silvia Varricchio, Stefania Staibano, Rosario Caltabiano

Summary: PRAME is a tumor antigen that can distinguish between benign nevi and malignant melanomas, and is also expressed in non-melanocytic tumors. This study found that PRAME expression is correlated with higher metastatic risk and lower metastasis-free survival in primary uveal melanoma. It suggests that PRAME can be included in immunohistochemical panels to predict metastatic risk and stratify patient outcomes.

PATHOLOGY RESEARCH AND PRACTICE (2023)

Review Oncology

Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion

Giuseppe Argenziano, Maria Concetta Fargnoli, Fabrizio Fantini, Massimo Gattoni, Giulio Gualdi, Francesco Pastore, Giovanni Pellacani, Pietro Quaglino, Paola Queirolo, Teresa Troiani

Summary: Cutaneous squamous cell carcinoma (CSCC) is a common skin malignancy with poor prognosis in advanced cases. A multi-disciplinary advisory group has proposed absolute and relative criteria for the use of cemiplimab in treating advanced CSCC.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

暂无数据